Anti-CD19 CAR T cells for refractory myasthenia gravis
Lancet Neurol
.
2023 Dec;22(12):1104-1105.
doi: 10.1016/S1474-4422(23)00375-7.
Authors
Aiden Haghikia
1
,
Tobias Hegelmaier
2
,
Denise Wolleschak
3
,
Martin Böttcher
3
,
Christiane Desel
2
,
Dominic Borie
4
,
Jeremias Motte
5
,
Georg Schett
6
,
Roland Schroers
7
,
Ralf Gold
5
,
Dimitrios Mougiakakos
3
Affiliations
1
Department of Neurology, Medical Faculty, Otto-von-Guericke University, Magdeburg 39120, Germany. Electronic address: aiden.haghikia@med.ovgu.de.
2
Department of Neurology, Medical Faculty, Otto-von-Guericke University, Magdeburg 39120, Germany.
3
Department of Haematology and Oncology, Otto-von-Guericke University, Magdeburg 39120, Germany.
4
Kyverna Therapeutics, Emeryville, CA, USA.
5
Department of Neurology, Ruhr University Bochum, Bochum, Germany.
6
Department of Rheumatology, Friedrich-Alexander-University, Erlangen, Germany.
7
Department of Haematology and Oncology, Ruhr University Bochum, Bochum, Germany.
PMID:
37977704
DOI:
10.1016/S1474-4422(23)00375-7
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
MeSH terms
Humans
Myasthenia Gravis* / therapy
T-Lymphocytes*